While pharmaceutical companies typically have more mature cybersecurity programs than many other factions within the healthcare sector, these firms also face complicated risks involving their expansive attack surfaces, complex manufacturing, distribution operations and sensitive intellectual property, said Joshua Mullen of Booz Allen Hamilton.
The supply chain in the pharmaceutical sector is a “complex, independent thing,” said Mullen, vice president and leader of Booz Allen Hamilton’s health and life sciences commercial business in an interview with Information Security Media Group.
“They’re facing such a large attack surface that they need to protect, and their adversaries only have to be right once, while they have to get it right 100% of the time,” he said.
“The smallest disruption in one part of the world can affect that quickly … and filter their way back to everyday Americans,” he said. “Whether that’s access to drugs and therapies, or access to medical records – the ability to go to your pharmacy and have that pharmacy verify that you’re insured and the price of the medication you’re seeking. So, we’ve seen these attacks happen.”
In this audio interview with Information Security Media Group (see audio link below photo), Mullen also discussed:
- Cybersecurity challenges involving the internet of things and operational technology devices in pharmaceutical and life sciences companies;
- Pharmaceutical industry cybersecurity considerations involving post-quantum computing;
- The use of zero trust, AI-enabled threat detection and red-teaming for bolstering cybersecurity in the pharmaceutical sector.
With 20 years of consulting experience, Mullen leads Booz Allen’s global commercial Health & Life Sciences and Commercial Financial Services business units. Mullen has spent the entirety of his consulting career in the security and technology spaces, focusing on topics ranging from business continuity and disaster recovery to the adoption and integration of new technologies and platforms in the security arena. Prior to his current role, Mullen spent time both in Booz Allen’s federal and commercial sales teams, as well as a stint in the firm’s capability delivery space as an analyst and facilitator.